In relation to the optimal sequencing of treatment in this setting, the phase 3 DREAMseq trial showed that the combination of nivolumab/ipilimumab followed by BRAF/MEK inhibitor therapy, if necessary, should be the preferred sequence for patients with BRAF-mutated advanced melanoma [17]. Here, MAP2K7 is linked to melanoma.